Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms

详细信息    查看全文

• 作者：Yanwen Jiang (1)
  Qing Yuan (1)
  Qiuhong Fang (1)
  
• 关键词：Lung cancer ; Docetaxel ; Gefitinib ; Synergy ; ERK
• 刊名：Journal of Cancer Research and Clinical Oncology
• 出版年：2014
• 出版时间：July 2014
• 年：2014
• 卷：140
• 期：7
• 页码：1087-1095
• 全文大小：
• 参考文献：1. Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445鈥?459 CrossRef
  2. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW et al (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081鈥?092 CrossRef
  3. Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi L, Galligioni A, Indraccolo S, Pasello G, Rea F, Favaretto A (2010) Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung. adenocarcinoma. Anticancer Res 30(12):5121鈥?128
  4. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621鈥?81 CrossRef
  5. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, Nyati MK (2006) Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 66:981鈥?88 CrossRef
  6. Davies AM, Ho C, Lara PN Jr et al (2006) Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 7:385鈥?88 CrossRef
  7. Eberhard DA, Johnson BE, Amler LC (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900鈥?909 CrossRef
  8. Furugaki K, Iwai T, Shirane M, Kondoh K, Moriya Y, Mori K (2010) Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS. Oncol Rep 24(5):1141鈥?146 CrossRef
  9. Gandara DR, Davies AM, Gautschi O, Mack PC, Lau DH, Lara PN Jr et al (2007) Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer 8(Suppl. 2):S61鈥揝67 CrossRef
  10. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, DeRosa F et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 25:1545鈥?552 CrossRef
  11. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial鈥擨NTACT 1. J Clin Oncol 22:777鈥?84 CrossRef
  12. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ (2008) Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer. Cells Mol Pharmacol 73:1290鈥?300 CrossRef
  13. Gow C-H, Chang Y-L, Hsu Y-C et al (2009) Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 20:696鈥?02 CrossRef
  14. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial鈥擨NTACT 2. J Clin Oncol 22:785鈥?94 CrossRef
  15. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225鈥?49 CrossRef
  16. Jiang Y, Li C, Ma Y, Chen J, Li Y, Chen L (2012) The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines. Clin Lab 58(5鈥?):551鈥?61
  17. Kim YH, Lee YJ (2006) Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity. J Cell Biochem 5:1284鈥?295 CrossRef
  18. Lee HH, Ye S, Li XJ, Lee KB, Park MH, Kim SM (2014) Combination treatment with paclitaxel and doxorubicin inhibits growth of human esophageal squamous cancer cells by inactivation of Akt. Oncol Rep 31:183鈥?88
  19. Li T, Ling YH, Goldman ID, Perez-Soler R (2007) Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 13:3413鈥?422 CrossRef
  20. Luk PP, Galettis P, Links M (2011) ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. Lung Cancer 12:7鈥?6 CrossRef
  21. MacKeigan JP, Taxman DJ, Hunter D, Earp HS 3rd, Graves LM, Ting JP (2002) Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 8:2091鈥?099
  22. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380鈥?388 CrossRef
  23. Mahaffey CM, Davies AM, Lara PN Jr et al (2007) Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmaco-dynamic separation. Clin Lung Cancer 8:548鈥?53 CrossRef
  24. Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Mio T, Mishima M (2011) Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy. Clin Lung Cancer 12:56鈥?1 CrossRef
  25. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947鈥?57 CrossRef
  26. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55鈥?3 CrossRef
  27. Piperdi B, Ling YH, Perez-Soler R (2007) Schedule dependent interaction between the proteosome inhibitor聽bortezomib and the EGFR-TK inhibitor erlotinib in NSCLC cell lines. J Thorac Oncol 2:715鈥?21 CrossRef
  28. Ramalingam S, Pawlish K, Gadgeel S, Demers R, Kalemkerian GP (1998) Lung cancer in young patients: analysis of a surveillance, epidemiology, and end results database. J Clin Oncol 16:651鈥?57
  29. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839鈥?44 CrossRef
  30. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA (2010) Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol. 28(31):4769鈥?777 CrossRef
  31. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169鈥?81 CrossRef
  32. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123鈥?32 CrossRef
  33. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163鈥?167 CrossRef
  34. Tianhong Li, Ling Y-H, Goldman ID et al (2007) Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non Small Cell Lung Cancer Cells. Clin Cancer Res 13:3413鈥?422 CrossRef
  35. Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer molecular and clinical predictors of outcome. N Engl J Med 353:133鈥?44 CrossRef
  36. Yacoub A, Han SI, Caron R, Gilfor D, Mooberry S, Grant S, Dent P (2003) Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. Cancer Biol Ther 6:670鈥?76
  
• 作者单位：Yanwen Jiang (1)
  Qing Yuan (1)
  Qiuhong Fang (1)
  
  1. Department of Respiratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People鈥檚 Republic of China
  
• ISSN：1432-1335

文摘

Background Tyrosine-kinase inhibitors (TKIs) and chemotherapy had different pharmacological mechanisms and therefore combined administration of TKIs and chemotherapy agents may have synergy. Our research aimed at exploring the cytotoxic interactions between gefitinib and docetaxel with different concentrations for non-small-cell lung cancer cell lines, and furthermore, the mechanisms underlying the cytotoxic synergism. Methods NCI-H1650 [epidermal growth factor receptor (EGFR) mutation and KRAS wild-type], NCI-H292 (EGFR wild-type and KRAS wild-type) and A549 (EGFR wild-type and KRAS mutation) cell lines were treated with docetaxel and/or gefitinib. Cytotoxic interactions, cell cycle distribution and cell signal pathway were analyzed, respectively. Results Cytotoxic interactions between docetaxel and gefitinib were dose-dependent and sequence-dependent in all these three cell lines. Docetaxel followed by gefitinib treatment was optimum regimen regardless of the mutation status of EGFR and KRAS. KRAS mutation and EGFR wild-type predicted insensitive to gefitinib and docetaxel combined treatment as well as gefitinib alone. G1 arrest was inconsistently associated with combination index (CI). However, apoptosis induction was schedule-dependent and can explain the synergism completely. Mitogen-activated protein kinase (MAPK) phosphorylation ratio was also schedule-dependent and positively correlated with CI. Conclusion Cytotoxic interactions between docetaxel and gefitinib were sequence-dependent regardless of the mutation status of EGFR and KRAS. Cell characteristic, apoptosis induction and MAPK phosphorylation but not cell cycle change may explain the molecular mechanisms of synergism.